A drug combo for early relapsed or refractory DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your lymphoma must be a type called diffuse large B-cell lymphoma (DLBCL) or a related high-grade B-cell lymphoma.
- Your lymphoma either came back within 12 months after your first treatment, or it never fully went away (refractory).
- Your first treatment must have included the drugs rituximab and an anthracycline (like doxorubicin).
- You must have at least one enlarged lymph node or tumor that can be measured on a PET or CT scan.
- Your heart, kidneys, liver, and blood counts must be working well enough (doctors will check with blood tests and a heart scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
This trial tests a new combination of three drugs (EZH2 inhibitor, glofitamab, and gemcitabine/oxaliplatin) for patients with diffuse large B-cell lymphoma that has stopped responding to or come back after prior treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
Hear when a new Diffuse Large B-cell Lymphoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.